Results 181 to 190 of about 67,411 (205)

Real-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011-2021). [PDF]

Curr Oncol
Aleksi A, Jobin KD, Hannouf MB, Husi P, Halperin H, White-Gloria C, Abedin T, Ruether D.   +7 more
europepmc   +1 more source

An integrative pharmacovigilance, network toxicology and molecular docking study on drug-induced cheilitis. [PDF]

Front Pharmacol
Wang X, Han S, Huang Y, Zhang L, Li X, Yang L, Zhang Y.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.

The Lancet Oncology, 2021
BACKGROUND Despite therapeutic advances in HER2-positive metastatic breast cancer, resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess the efficacy and safety of pyrotinib (an irreversible pan-HER inhibitor) plus ...
Bing-he Xu, M. Yan, F. Ma, Xichun Hu, Jifeng Feng, Q. Ouyang, Z. Tong, Huiping Li, Qingyuan Zhang, T. Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Yuanting Gu, Qianjun Chen, Jinping Liu, Jing Cheng, C. Geng, S. Qin, Shusen Wang, Jinsong Lu, K. Shen, Qiang Liu, Xiaojian Wang, Hong Wang, T. Luo, Jin Yang, Yudong Wu, Zhiyong Yu, Xiaoyu Zhu, Chunxia Chen, J. Zou   +32 more
semanticscholar   +1 more source

5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review).

Oncology Report, 2023
Although 5‑fluorouracil (5‑FU)‑based chemotherapy is the major treatment for colorectal cancer, it has disadvantages such as systemic toxicity, lack of effectiveness and selectivity, and development of resistance.
S. M. Alzahrani, H. A. Al Doghaither, Ayat B. Al-Ghafari, P. Pushparaj   +3 more
semanticscholar   +1 more source

Quince seed mucilage/β-cyclodextrin/Mmt-Na+-co-poly (methacrylate) based pH-sensitive polymeric carriers for controlled delivery of Capecitabine.

International Journal of Biological Macromolecules, 2023
In current work, quince seed mucilage and β-Cyclodextrin based pH regulated hydrogels were developed using aqueous free radical polymerization to sustain Capecitabine release patterns and to overcome its drawbacks, such as high dose frequency, short half-
Tahira Yasmin, Asif Al Mahmood, Muhammad Farooq, Umaira Rehman, R. M. Sarfraz, Hira Ijaz, M. R. Akram, Abir Boublia, Mounir M. Salem Bekhit, Barbara Ernst, Y. Benguerba   +10 more
semanticscholar   +1 more source

Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial

Hepatology, 2023
Background and Aims: The effectiveness of gemcitabine-based adjuvant chemotherapy is unclear in cholangiocarcinoma. We investigated the role of adjuvant gemcitabine plus cisplatin (GemCis) in a homogeneous group of high-risk patients with resected, lymph
H. Jeong, Kyu-pyo Kim, J. Jeong, D. Hwang, Jae Hoon Lee, Ki-Hun Kim, D. Moon, Myung-Ah Lee, Se Jun Park, H. Chon, Jin-hong Park, Ji Sung Lee, B. Ryoo, C. Yoo   +13 more
semanticscholar   +1 more source

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.

The Lancet, 2021
BACKGROUND Patients with locoregionally advanced nasopharyngeal carcinoma have a high risk of disease relapse, despite a high proportion of patients attaining complete clinical remission after receiving standard-of-care treatment (ie, definitive ...
Yupei Chen, Xu Liu, Qin C Zhou, Kun-yu Yang, F. Jin, Xiao-dong Zhu, M. Shi, G. Hu, Wei‐han Hu, Yan Sun, Hong-fen Wu, Hui Wu, Q. Lin, Hui Wang, Ye Tian, Ning Zhang, Xicheng Wang, Liangfang Shen, Zheng-Zheng Liu, Jing-yu Huang, Xiuling Luo, Ling Li, J. Zang, Q. Mei, B. Zheng, D. Yue, Jing Xu, San-Gang Wu, Yan-Xia Shi, Y. Mao, Lei Chen, Wen-Fei Li, G. Zhou, R. Sun, R. Guo, Yuan Zhang, Cheng Xu, J. Lv, Ying Guo, Hui-xia Feng, Ling-Long Tang, F. Xie, Ying Sun, Jun Ma   +43 more
semanticscholar   +1 more source